Integer (NYSE:ITGR) Raised to “Hold” at Zacks Research

Integer (NYSE:ITGR) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other equities analysts have also commented on ITGR. Piper Sandler reissued an “overweight” rating and set a $97.00 price target (up from $87.00) on shares of Integer in a research report on Friday, May 1st. Truist Financial increased their price objective on shares of Integer from $97.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. KeyCorp reiterated an “overweight” rating and set a $104.00 price objective on shares of Integer in a research note on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Integer in a research report on Thursday, June 18th. Finally, Citigroup upped their target price on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Integer has an average rating of “Hold” and an average target price of $97.00.

Integer Trading Down 0.0%

Shares of ITGR opened at $96.05 on Monday. The stock’s 50-day moving average is $91.97 and its two-hundred day moving average is $87.81. The stock has a market cap of $3.26 billion, a PE ratio of 23.95, a P/E/G ratio of 2.29 and a beta of 0.64. Integer has a 12 month low of $62.00 and a 12 month high of $116.31. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.75 and a quick ratio of 2.38.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.21 by ($0.01). Integer had a return on equity of 12.83% and a net margin of 7.64%.The company had revenue of $439.58 million during the quarter, compared to analysts’ expectations of $426.48 million. During the same period in the previous year, the company earned $1.31 EPS. Integer’s quarterly revenue was up .5% on a year-over-year basis. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. Equities analysts forecast that Integer will post 6.04 earnings per share for the current fiscal year.

Institutional Trading of Integer

Institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in Integer by 48.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 117 shares during the last quarter. Salomon & Ludwin LLC grew its stake in shares of Integer by 46.8% in the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 118 shares during the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Integer by 0.6% in the 4th quarter. Kestra Advisory Services LLC now owns 21,424 shares of the medical equipment provider’s stock worth $1,680,000 after purchasing an additional 136 shares in the last quarter. Orion Porfolio Solutions LLC raised its holdings in shares of Integer by 1.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 9,755 shares of the medical equipment provider’s stock worth $1,200,000 after purchasing an additional 138 shares in the last quarter. Finally, Lido Advisors LLC lifted its stake in Integer by 5.5% during the fourth quarter. Lido Advisors LLC now owns 2,887 shares of the medical equipment provider’s stock valued at $226,000 after purchasing an additional 151 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.